4Front Ventures (FFNTF) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	000-56075
Entity Registrant Name	4Front Ventures Corp.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	83-4168417
Entity Address, Address Line One	5060 N. 40th Street
Entity Address, Address Line Two	Suite 120
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85018
City Area Code	602
Local Phone Number	633-3067
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		640,386,686
Entity Central Index Key	0001783875
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Class A Subordinate Voting Share
Document Information [Line Items]
Title of 12(b) Security	Class A Subordinate Voting Shares, no par value
Trading Symbol	FFNTF
Security Exchange Name	NONE
ADR
Document Information [Line Items]
Title of 12(b) Security	Class A Subordinate Voting Shares, no par value
Trading Symbol	FFNT
Security Exchange Name	NONE

CONDENSED CONSOLIDATED INTERIM

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 5,286	$ 22,581
Accounts receivable, net	8,722	1,946
Other receivables	20	289
Current portion of lease receivables	3,765	3,630
Inventory	30,936	20,087
Current portion of notes receivable	0	109
Prepaid expenses and other assets	2,392	2,232
Total current assets	51,121	50,874
Property, plant, and equipment, net	58,697	42,633
Lease receivables	5,942	6,748
Intangible assets, net	54,452	26,246
Goodwill	41,393	23,155
Right-of-use assets	103,229	100,519
Deposits	5,165	5,364
TOTAL ASSETS	319,999	255,539
Current liabilities:
Accounts payable	11,303	2,131
Accrued expenses and other current liabilities	11,620	9,411
Taxes payable	32,805	23,968
Derivative liability	8	3,502
Current portion of contract liabilities	653	0
Current portion of convertible notes	0	2,784
Current portion of lease liability	3,428	3,629
Current portion of notes payable and accrued interest	9,299	3,413
Total current liabilities	69,116	48,838
Convertible notes	15,513	14,641
Notes payable and accrued interest from related party	49,422	48,266
Long term notes payable	10,279	1,709
Long term accounts payable	1,200	1,200
Contract liabilities	2,000	0
Contingent consideration payable	0	2,393
Construction finance liability	16,000	0
Deferred tax liability	6,884	7,849
Lease liability	100,322	93,111
TOTAL LIABILITIES	270,736	218,007
SHAREHOLDERS' EQUITY
Equity attributable to 4Front Ventures Corp.	304,602	274,120
Additional paid-in capital	54,487	52,197
Deficit	(309,913)	(288,857)
Non-controlling interest	87	72
TOTAL SHAREHOLDERS' EQUITY	49,263	37,532
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 319,999	$ 255,539

CONDENSED CONSOLIDATED INTERI_2

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
REVENUE
Revenue from sale of goods	$ 29,067	$ 23,126	$ 77,638	$ 67,658
Real estate income	3,407	2,815	9,323	8,374
Total revenues	32,474	25,941	86,961	76,032
Cost of goods sold	(17,427)	(10,269)	(46,144)	(30,210)
Gross profit	15,047	15,672	40,817	45,822
OPERATING EXPENSES
Selling and marketing expenses	5,462	5,992	16,955	17,863
General and administrative expenses	7,126	7,170	21,336	17,418
Depreciation and amortization	1,020	831	2,990	2,466
Transaction and restructuring related expenses	60	0	2,069	0
Equity based compensation	862	2,603	2,290	7,978
Total operating expenses	14,530	16,596	45,640	45,725
Income (loss) from operations	517	(924)	(4,823)	97
Other income (expense)
Interest income	6	2	8	13
Interest expense	(4,157)	(2,532)	(10,195)	(7,894)
Amortization of loan discount upon conversion of debt to equity	0	0	0	(2,915)
Change in fair value of derivative liability	420	3,345	3,494	502
Gain on contingent consideration	0	0	2,393	0
Loss on litigation settlement	(250)	0	(250)	0
Loss on lease termination	0	0	0	(1,210)
Other	(1,815)	56	(1,866)	56
Total other income (expense), net	(5,796)	871	(6,416)	(11,448)
Net loss before income taxes	(5,279)	(53)	(11,239)	(11,351)
Income tax expense	(3,322)	(4,541)	(9,802)	(10,545)
Net loss	(8,601)	(4,594)	(21,041)	(21,896)
Net income attributable to non-controlling interest	5	5	15	15
Net loss attributable to shareholders	$ (8,606)	$ (4,599)	$ (21,056)	$ (21,911)
Basic loss per share (in dollar per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.04)
Diluted loss per share (in dollar per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.04)
Weighted average number of shares outstanding, basic (in shares)	639,624,851	592,631,092	632,048,250	590,084,188
Weighted average number of shares outstanding, diluted (in shares)	639,624,851	592,631,092	632,048,250	590,084,188

CONDENSED CONSOLIDATED INTERI_3

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Total 4Front Ventures Corp. Shareholders' Equity	Share Capital	Additional Paid-In Capital	Deficit	Non-Controlling Interest
Beginning balance (in shares) at Dec. 31, 2020			538,851,252
Beginning Balance at Dec. 31, 2020	$ 42,203	$ 42,151	$ 250,583	$ 42,116	$ (250,548)	$ 52
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued for earnout (in shares			473,491
Shares issued for earnout	161	161	$ 161
Share-based compensation	2,396	2,396		2,396
Conversion of notes to equity (in shares)			24,366,003
Conversion of notes to equity	6,253	6,253	$ 6,253
Shares issued with exercise of warrants (in shares)			2,422,363
Shares issued with exercise of warrants	1,563	1,563	$ 1,563
Shares issued with exercise of stock options (in shares)			1,358,116
Shares issued with exercise of stock options	871	871	$ 871
Return of treasury shares (in shares)			(8,320)
Net loss	(11,084)	(11,089)			(11,089)	5
Ending balance (in shares) at Mar. 31, 2021			567,462,905
Ending Balance at Mar. 31, 2021	42,363	42,306	$ 259,431	44,512	(261,637)	57
Beginning balance (in shares) at Dec. 31, 2020			538,851,252
Beginning Balance at Dec. 31, 2020	42,203	42,151	$ 250,583	42,116	(250,548)	52
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(21,896)
Ending balance (in shares) at Sep. 30, 2021			593,920,448
Ending Balance at Sep. 30, 2021	51,579	51,512	$ 273,877	50,094	(272,459)	67
Beginning balance (in shares) at Mar. 31, 2021			567,462,905
Beginning Balance at Mar. 31, 2021	42,363	42,306	$ 259,431	44,512	(261,637)	57
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued for earnout (in shares			535,018
Shares issued for earnout	722	722	$ 722
Share-based compensation	2,979	2,979		2,979
Conversion of notes to equity (in shares)			24,676,794
Conversion of notes to equity	11,466	11,466	$ 11,466
Shares issued with exercise of warrants (in shares)			570,864
Shares issued with exercise of warrants	1,813	1,813	$ 1,813
Shares issued with exercise of stock options (in shares)			652,940
Shares issued with exercise of stock options	443	443	$ 443
Net loss	(6,218)	(6,223)			(6,223)	5
Ending balance (in shares) at Jun. 30, 2021			593,898,521
Ending Balance at Jun. 30, 2021	53,568	53,506	$ 273,875	47,491	(267,860)	62
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	2,603	2,603		2,603
Shares issued with exercise of stock options (in shares)			21,927
Shares issued with exercise of stock options	2	2	$ 2
Net loss	(4,594)	(4,599)			(4,599)	5
Ending balance (in shares) at Sep. 30, 2021			593,920,448
Ending Balance at Sep. 30, 2021	$ 51,579	51,512	$ 273,877	50,094	(272,459)	67
Beginning balance (in shares) at Dec. 31, 2021	594,181,604		594,181,604
Beginning Balance at Dec. 31, 2021	$ 37,532	37,460	$ 274,120	52,197	(288,857)	72
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued pursuant to acquisition (in shares)			28,571,428
Shares issued pursuant to acquisition	18,200	18,200	$ 18,200
Share-based compensation	1,038	1,038		1,038
Conversion of notes to equity (in shares)			6,235,512
Conversion of notes to equity	3,122	3,122	$ 3,122
Shares issued with exercise of warrants (in shares)			88,659
Shares issued with exercise of warrants	50	50	$ 50
Net loss	(5,894)	(5,899)			(5,899)	5
Ending balance (in shares) at Mar. 31, 2022			629,077,203
Ending Balance at Mar. 31, 2022	$ 54,048	53,971	$ 295,492	53,235	(294,756)	77
Beginning balance (in shares) at Dec. 31, 2021	594,181,604		594,181,604
Beginning Balance at Dec. 31, 2021	$ 37,532	37,460	$ 274,120	52,197	(288,857)	72
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (21,041)
Ending balance (in shares) at Sep. 30, 2022	641,662,894		641,662,894
Ending Balance at Sep. 30, 2022	$ 49,263	49,176	$ 304,602	54,487	(309,913)	87
Beginning balance (in shares) at Mar. 31, 2022			629,077,203
Beginning Balance at Mar. 31, 2022	54,048	53,971	$ 295,492	53,235	(294,756)	77
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued pursuant to acquisition (in shares)			8,783,716
Shares issued pursuant to acquisition	6,245	6,245	$ 6,245
Warrants issued for to acquisition	732	732	$ 732
Share-based compensation	390	390		390
Shares issued with exercise of stock options (in shares)			51,975
Shares issued with exercise of stock options	33	33	$ 33
Net loss	(6,546)	(6,551)			(6,551)	5
Ending balance (in shares) at Jun. 30, 2022			637,912,894
Ending Balance at Jun. 30, 2022	54,902	54,820	$ 302,502	53,625	(301,307)	82
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued pursuant to acquisition (in shares)			3,750,000
Shares issued pursuant to acquisition	2,100	2,100	$ 2,100
Share-based compensation	862	862		862
Shares issued with exercise of stock options (in shares)
Shares issued with exercise of stock options	0	0
Net loss	$ (8,601)	(8,606)			(8,606)	5
Ending balance (in shares) at Sep. 30, 2022	641,662,894		641,662,894
Ending Balance at Sep. 30, 2022	$ 49,263	$ 49,176	$ 304,602	$ 54,487	$ (309,913)	$ 87

CONDENSED CONSOLIDATED INTERI_4

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (21,041)	$ (21,896)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
Depreciation and amortization	6,844	3,668
Equity based compensation	2,290	7,978
Change in fair value of derivative liability	(3,494)	(502)
Gain on contingent consideration	(2,393)	0
Accretion of lease liability	735	726
Accretion of lease receivable	671	487
Write-off of fixed asset from terminated lease	0	1,210
Accretion of construction financing liability	1,143	0
Accretion of contingent consideration	0	228
Accretion of convertible debenture and interest	872	4,121
Accrued interest on notes payable	6,483	4,783
Deferred taxes	(965)	632
Changes in operating assets and liabilities	6,876	2,533
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	(1,979)	3,968
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisitions, net of cash acquired (Note 5)	(24,547)	0
Proceeds on note receivable	109	183
Sale of dispensaries and interests in cannabis licenses	0	1,093
Purchases of property and equipment	(2,535)	(14,021)
NET CASH USED IN INVESTING ACTIVITIES	(26,973)	(12,745)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of contingent consideration	(412)	(1,204)
Proceeds from issuance of construction financing liability	16,000	0
Payment on construction financing liability	(1,143)	0
Issuance of notes payable	3,000	0
Proceeds from the exercise of warrants	50	1,664
Proceeds from the exercise of stock options	33	1,315
Payments of notes payable	(5,871)	(3,453)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	11,657	(1,678)
NET DECREASE IN CASH	(17,295)	(10,455)
CASH, BEGINNING OF PERIOD	22,581	18,932
CASH, END OF PERIOD	$ 5,286	$ 8,477

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION 4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. The Company operates the business through two segments, THC Cannabis and CBD Wellness. The Company's THC Cannabis segment consists of six dispensaries and nine production and cultivation facilities across Illinois, Michigan, Massachusetts, and California. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies and intellectual property to cannabis producers in the state of Washington. The Company’s CBD Wellness segment sells non-THC hemp derived products across the United States. The unaudited condensed consolidated interim financial statements include the accounts of 4Front and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company has prepared these statements pursuant to the rules and regulations of the United States Securities and Exchange Commission (SEC) and U.S. GAAP. Certain information related to the organization, significant accounting policies, and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted. In the opinion of management, the financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. Operating results for interim periods are not necessarily indicative of results you can expect for a full year. These financials should be read in conjunction with our audited consolidated financial statements and notes thereto appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Management's Estimates and Assumptions The preparation of the Company’s financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. Actual results may differ from these estimates. The most critical and subjective areas are discussed in detail in the notes in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. There have been no changes to the Company's accounting policies since the Annual Report with one notable addition documented below. Contract Assets and Liabilities A contract liability is recorded on the consolidated balance sheet for consideration transferred prior to goods transfer. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified as current portion of contract liabilities in the accompanying condensed balance sheets with the remaining balance classified as long term. When the Company has an unconditional right to payment, a receivable is recorded on the consolidated balance sheet as current portion of contract assets for contract assets due within twelve months or contract assets in long term assets for amounts due after twelve months. The accompanying condensed balance sheets reflect a contract liability for the amount of revenue to be recognized in the future as and when the Company satisfies its remaining performance obligations. As of September 30, 2022, the Company has recognized $2.7 million of contract liabilities of which $0.7 million are recorded as current liabilities and $2 million are recorded as long term liabilities. New Accounting Pronouncements Accounting Standard Updates Issued but Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurements - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	INVENTORY The Company’s inventories include the following as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 Raw materials - unharvested cannabis $ 4,584 $ 2,164 Raw materials - harvested and purchased cannabis 12,425 3,045 Packaging and other non-finished goods 3,547 1,734 Work in process - manufactured and purchased extracts 2,124 4,771 Finished goods 8,256 8,373 Total $ 30,936 $ 20,087

Property Plant and Equipment

Property Plant and Equipment	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment and related depreciation are summarized in the table below: September 30, 2022 December 31, 2021 Land $ 775 $ — Buildings & improvements 14,253 1,483 Construction in process 328 63 Furniture, equipment & other 19,422 13,425 Leasehold improvements 36,623 35,538 Total $ 71,401 $ 50,509 Less: accumulated depreciation (12,704) (7,876) Total property, plant, and equipment, net $ 58,697 $ 42,633 Approximately $33 million of property and equipment is secured by LI Lending as collateral on the LI Lending note (Note 7). There were no significant contractual commitments for future capital expenditures as of September 30, 2022 and December 31, 2021. Depreciation expense for the nine months ended September 30, 2022 and 2021 was $4.8 million and $1.8 million, respectively, of which $3.9 million and $1.2 million, respectively, is included in cost of goods sold. Depreciation expense for the three months ended September 30, 2022 and 2021 was $1.4 million and $0.7 million, respectively, of which $1.2 million and $0.5 million, respe ctively, is included in cost of goods sold.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible Assets Intangible assets and related amortization are summarized in the table below: Licenses Customer Relationships Non-Competition Agreements Know-How Tradenames and Trademarks Total Balance, December 31, 2021 $ 20,146 $ 1,088 $ — $ 5,012 $ — $ 26,246 Acquisitions (Note 5) 26,700 — — — 3,522 30,222 Amortization expense — (437) — (1,455) (124) (2,016) Balance, September 30, 2022 $ 46,846 $ 651 $ — $ 3,557 $ 3,398 $ 54,452 Goodwill Balance, December 31, 2021 $ 23,155 Acquisitions (Note 5) 18,238 Balance, September 30, 2022 $ 41,393 Impairment of Intangible Assets and Goodwill The goodwill is related to the THC Cannabis segment, and there has been no accumulated impairment within this segment. The CBD Wellness segment has an accumulated impairment charge of $13.4 million, which represents the entire balance and occurred during the year-ended December 31, 2020. As of September 30, 2022 and December 31, 2021 all goodwill and intangibles are attributable to the THC Cannabis segment. Goodwill and infinite lived assets are assessed on an annual basis for impairment, or more frequently, if circumstances indicate an impairment to the carrying value may have occurred. As of September 30, 2022, the Company believes that the carrying amounts of the long-lived assets, including finite-lived intangible assets (licenses), are recoverable and there were no events or circumstances that indicated impairment. However, if adverse events were to occur or circumstances were to change indicating that the carrying amount of such assets may not be fully recoverable, the assets would be reviewed for impairment.

Acquisitions And Business Combi

Acquisitions And Business Combinations	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Business Combinations	ACQUISITIONS AND BUSINESS COMBINATIONS New England Cannabis Company (NECC) Merger Agreement On January 28, 2022, the Company completed an acquisition for 100% of NECC for cash consideration of $9 million and 28.6 million of Class A Subordinate Voting shares of the Company (the “SVS”). The acquisition increased the Company's presence in Massachusetts and the northeastern United States and provides additional opportunities for expansion in the Northeast. In connection with the consummation of the NECC Merger on January 28, 2022, Mission Partners RE, LLC, a Delaware limited liability company wholly owned by the Company completed its acquisition of 100% of the issued and outstanding membership interests of 29 Everett Street LLC, a Massachusetts limited liability company (the “Everett LLC”) for cash consideration of $16 million and a promissory note of $2 million. The Everett LLC entity was solely comprised of property plant and equipment that was leased to and used by NECC at the time of the transaction and consolidated into NECC operations post acquisition. The Merger and Purchase Agreement were recorded as one transaction (collectively, referred to as the "NECC Acquisitions"), as the entities were commonly owned by the same individual and the purchase of Everett LLC was contingent on the Merger with NECC. The preliminary purchase price allocation for the NECC acquisition is reflected in the table below and remains subject to revisions as additional information is obtained about the facts and circumstances that existed at the valuation date. The preliminary allocation of purchase price, including the value of certain tangible and intangible assets acquired and liabilities assumed is based on the best estimates of management and is subject to revision based on the final valuations. We do not expect goodwill and intangible assets will be deductible for tax purposes. The following tables present the preliminary purchase price allocation for the NECC Merger: Cash consideration $ 25,000 Note to seller 2,000 Equity consideration - common stock 18,200 Total Purchase Price $ 45,200 Description Fair value Assets acquired: Cash $ 2 Inventory 213 Prepaid assets 2 Property, plant, and equipment 16,000 Intangible asset - licenses 18,000 Total assets acquired $ 34,217 Liabilities assumed: Accounts payable 800 Total liabilities assumed $ 800 Estimated fair value of net assets acquired $ 33,417 Estimated Goodwill $ 11,783 As part of the NECC Merger, the Company incurred $0.7 million in transaction and restructuring costs, which were included in transaction and restructuring related expenses and expensed as incurred. Island Merger Agreement On April 25, 2022, the Company completed a merger acquisition for 100% of Island Global Holdings for non-cash consideration as follows: (i) 8,783,716 Class A Subordinated Voting Shares of the Company (the “SVS”); (ii) 6% 54-month, subordinated promissory notes (the “Island Merger Notes”) in the aggregate principal amount of $10.0 million; and (iii) warrants to purchase 2,999,975 SVS at a price of $1.00 per SVS. This acquisition enhanced the Company's growing brand portfolio, including diverse lines of pre-rolls, flower and infused products. The preliminary purchase price allocation for the Island acquisition is reflected in the table below and remains subject to revisions as additional information is obtained about the facts and circumstances that existed at the valuation date. The preliminary allocation of purchase price, including the value of certain tangible and intangible assets acquired and liabilities assumed, is based on the best estimates of management and subject to revision based on the final valuations. We do not expect goodwill and intangible assets will be deductible for tax purposes. The following tables present the preliminary purchase price allocation for the Island Merger: Note to seller $ 10,000 Equity consideration - common stock 6,245 Equity consideration - warrants 732 Total Purchase Price $ 16,977 Description Fair value Assets acquired: Cash $ 458 Accounts receivable 511 Inventory 3,072 Prepaid expenses and other current assets 424 Property and equipment, net 2,214 Operating lease - right of use asset 10,227 Intangible assets 11,300 Total assets acquired $ 28,206 Liabilities assumed: Accounts payable $ 1,356 Accrued expenses and other liabilities 2,566 Contract liabilities 3,535 Lease liabilities 10,227 Total liabilities assumed 17,684 Estimated fair value of net assets acquired $ 10,522 Estimated Goodwill $ 6,455 The intangible assets acquired by the Company consist of cannabis licenses, trade names and trademarks for operations. Utilizing like licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets and the trade names and trademarks have a life of ten years. As part of the Island Merger, the Company incurred $1.3 million in restructuring and transaction costs, which were included in transaction and restructuring related expenses and expensed as incurred. Bloom Farms On August 19, 2022, the Company completed an asset acquisition to acquire certain assets of Bloom Farms for stock consideration of 3,750,000 class A subordinate voting shares valued at $2.1 million. In addition to the contracted purchase price, the Company incurred $0.06 million in transactional costs that were capitalized as part of the asset acquisition. This transaction increased the Company's brand portfolio in the California market. Share Consideration $ 2,100 Transaction Costs 6 Total Purchase Price $ 2,106 In addition to the consideration transferred, there is an earn-out consideration based on the actual revenue in excess of $2.1 million generated from the brands within California during the first 12 months after the closing. This earn-out consideration cannot exceed $5 million. As of the transaction date, it is not probable this consideration will become payable and no liability has been recognized. If the contingency becomes payable, the Company will recognize the amount in the measurement of the cost of the acquired assets. The allocation of the asset acquisition cost is detailed below: Description Fair Value Assets acquired: Accounts receivable $ 508 Inventory 534 Equipment 142 Intangible assets - tradenames 922 Total assets acquired $ 2,106 Unaudited Pro Forma Results The following unaudited pro forma financial information presents the results of operations of the Company, NECC, and Island for the nine months ended September 30, 2022 and 2021, as if the acquisitions had occurred as of January 1, 2021. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during those periods. The unaudited pro forma financial information for the Company including NECC and Island is as follows: For the For the Three Months Ended September 30, 2022 2021 Reported Proforma Reported Proforma Revenues $ 32,474 $ 32,474 $ 25,941 $ 28,238 (Loss) income from operations 517 517 (924) (2,603) Net loss $ (8,601) $ (8,601) $ (4,594) $ (8,103) Basic and diluted earning (loss) per share $ (0.01) $ (0.01) $ (0.01) $ (0.01) For the For the Nine Months Ended September 30, 2022 2021 Reported Proforma Reported Proforma Revenues $ 86,961 $ 88,689 $ 76,032 $ 81,524 (Loss) income from operations (4,823) (5,875) 97 (5,093) Net loss $ (21,041) $ (27,235) $ (21,896) $ (28,916) Basic and diluted earning (loss) per share $ (0.03) $ (0.04) $ (0.04) $ (0.05) Acquisition Related Results For the NECC and Island acquisitions, the Company's consolidated results of operations included acquisition related revenue of $2.5 million and $3.5 million and net income of $1.8 million and net loss $0.1 million f

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	LEASES The Company as a Lessor: The Company leases a building in Elma, Washington that is subleased by the Company to a third party. This sublease is classified as a finance lease with a long term lease receivable balance of $5.9 million and $6.7 million and a short term lease receivable balance of $3.8 million and $3.6 million as of September 30, 2022 and December 31, 2021, respectively. This lease generated $0.6 million and $0.7 million in real estate income for the three months ended September 30, 2022 and 2021, respectively. This lease generated $2.0 million and $2.1 million in real estate income for the nine months ended September 30, 2022 and 2021, respectively. The Company owned buildings in Olympia, Washington that were leased to a third party. This lease was classified as a finance lease. On December 17, 2020, the Company sold the Olympia building and other assets as part of a sale and leaseback transaction and this lease was cancelled. The Company applied ASC 842 to a new sublease to the same thi rd party and classified the new sublease as an operating lease. The lease receivable was sold to the purchaser of the assets as part of the sale and leaseback transaction. This lease generated $2.3 million and $2.1 million in real estate income for the three months ended September 30, 2022 and 2021, respectively. This lease generated $6.8 million and $6.3 million in real estate income for the nine months ended September 30, 2022 and 2021, respectively. The following table summarizes changes in the Company’s lease receivables: September 30, 2022 December 31, 2021 Balance, beginning of the year $ 10,378 $ 11,045 Interest 2,029 2,783 Lease payments received (2,700) (3,450) Balance, end of the period 9,707 $ 10,378 Less current portion (3,765) (3,630) Long-term lease receivables $ 5,942 $ 6,748

Notes Payable and Convertible N

Notes Payable and Convertible Notes	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes	NOTES PAYABLE AND CONVERTIBLE NOTES The Company’s notes payable and convertible notes are as follows: LI Lending, LLC May 2020 Convertible Notes May 2020 Convertible Notes (Swap) October 2021 Convertible Note Other Loans Total Balance, December 31, 2020 $ 45,362 $ 2,855 $ 11,867 $ — $ 6,931 $ 67,015 Loans advanced, net — — — 14,376 930 15,306 Loan payments (4,671) — — — (1,079) (5,750) Converted to equity — (5,852) (11,867) — — (17,719) Accrued interest 7,575 2,997 — 265 1,124 11,961 Balance, December 31, 2021 $ 48,266 $ — $ — $ 14,641 $ 7,906 $ 70,813 Loans advanced, net — — — — 15,000 15,000 Loan payments (4,689) — — — (1,182) (5,871) Converted to equity — — — — (2,784) (2,784) Accrued interest 5,845 — — 872 638 7,355 Balance, September 30, 2022 $ 49,422 $ — $ — $ 15,513 $ 19,578 $ 84,513 Less current portion — — — — (9,299) (9,299) Long-term portion $ 49,422 $ — $ — $ 15,513 $ 10,279 $ 75,214 Convertible Notes On May 14, 2020, the Company issued $5.8 million in convertible notes to existing investors in the Company. The notes pay interest of 5% per annum and have a maturity date of February 28, 2022. The notes can be converted into SVS of the Company for $0.25 per share at any time at the option of the holder. The Company was permitted to require mandatory conversion at any time that the Company’s stock price remains above $0.50 for 45 consecutive days. In 2021, the Company enacted the mandatory conversion feature and converted the May 2020 Convertible Note balance to subordinate voting shares. As part of issuing the convertible notes, the investors were given the right to exchange stock in the Company into separate convertible notes (swap notes). In total 29,448,468 shares with a value of $13.7 million were exchanged for $13.7 million in convertible notes. These notes were effective May 28, 2020, have a maturity date of May 28, 2025, and can be converted into Class A Subordinate Voting Shares of the Company for $0.46 per share at any time at the option of the holder. The notes pay no interest if the Company’s annual revenue is greater than $15 million, and 3% annually otherwise. The Company can require mandatory conversion at any time that the Company’s stock price remains above $0.92 for 45 consecutive days. In 2021, the Company exercised the mandatory conversion feature and converted the May 2020 Convertible Note (Swap) balance to subordinate voting shares. On October 6, 2021, the Company entered into a convertible promissory note purchase agreement for $15 million, less issuance costs of $0.6 million, resulting in net proceeds of $14.4 million. The notes pay interest of 6% per annum and have a maturity date of October 6, 2024. The notes can be converted into SVS of the Company for $1.03 per share at any time at the option of the holder. As of September 30, 2022, no payments have been made for this loan. LI Lending LLC On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for $50 million. LI Lending LLC is related because an officer of the Company is a part-owner of LI Lending LLC. As of September 30, 2022, the Company had drawn $45 million on the loan in two amounts, an initial $35 million and a final $10 million, both bearing a 10.25% and 12.25% interest rate, respectively. The outstanding balance as of September 30, 2022 is $49.7 million, less debt discount of $0.3 million, for a net balance of $49.4 million. See Note 11 for further discussion of this related party transaction. In April 2020, the loan was amended. In exchange for consent to allow the sale of the Pennsylvania and Maryland assets and the release of related collateral, the Company agreed to make prepayments of principal to LI Lending LLC in the amount of $0.3 million per month for an eight-month period beginning on May 1, 2020. The $2 million prepayment was applied to the initial $35 million amount, decreasing the balance to $33 million. Additionally, the Company agreed to pay an increased interest rate of 12.25% on the final $10 million of the loan until such time as this amount has been paid down, with the initial $33 million amount continuing to be subject to the original 10.25% interest rate. In December 2020, the loan was amended to allow for the release of collateral for the failed sale leaseback transaction described in Note 7 below, which was entered into with Innovative Industrial Properties, Inc. (“IIPR”). The amendment increased both interest rates by 2.5% on the loan amounts but allowed the payments resulting from the incremental interest to be deferred until January 1, 2022. The Company elected to defer payment, and the additional 2.5% interest is accrued each month and added to the balance of the loan. The Company was required to make interest-only payments monthly of 10.25% on the initial $33 million and 12.25% on the final $10 million of the loan until January 1, 2022 when the interest rates of 12.75% for the initial $33 million and 14.75% for the final $10 million took effect for the remaining term. The loan matures on May 10, 2024. An exit fee of 20% of the principal balance will be due as principal is repaid. Accrued interest expense of $5.8 million includes a loan discount accretion expense of $0.2 million for the nine months ended September 30, 2022. Accrued interest expense of $2.5 million includes a loan discount accretion expense of $0.04 million for the three months ended September 30, 2022. On January 1, 2022, the Company began making the required principal payments in addition to the interest payments for this loan. As of September 30, 2022, the Company has made $4.7 million in payments on this loan. Other Outstanding as of September 30, 2022 were other payables totaling $19.6 million which include notes issued as part of the acquisitions of Healthy Pharms, NECC, Island, and Arkansas entities as follows: Subsidiary Terms September 30, 2022 December 31, 2021 Healthy Pharms Inc. Unsecured convertible note, due November 18, 2021 at 12% per annum $ — $ 2,784 Healthy Pharms Inc. Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1) 3,463 3,213 Island Global Holdings, Inc. Promissory note due October 25, 2026 at 6% per annum 10,279 — NECC Promissory note due November 15, 2022 at 10% per annum (2) 1,005 — Island Global Holdings, Inc. Promissory note due February 28, 2023 at 1.5% per month (3) 3,057 — Arkansas Entities Unsecured Promissory note due December 1,2022, monthly interest payments at 14% per annum 1,730 1,709 Equipment Loans Secured by equipment, monthly payments beginning in 2021 at 15% per annum 44 49 Other Various — 151 Total Notes Payable and Convertible Notes $ 19,578 $ 7,906 (1) In November 2021, the unsecured promissory note was modified to be due and payable in full on or before December 18, 2022. The Company concluded the extension resulted in a debt modification under ASC 470 . (2) On July 28, 2022, the parties amended the promissory note to provide for payment of half the principal on the initial maturity date, and the remaining principal and all accrued interest on November 15, 2022. Interest will continue at annual rate of ten percent (10%). (3) On August 30, 2022, the Company entered into a Promissory Note Purchase Agreement with HI 4Front, LCC and Navy Capital Green Fund, LP. Under the agreement, the Company sold promissory notes totaling $3 million with a six-month maturity bearing 1.5% monthly interest for three months and 2% monthly interest for three months. The notes were unsecured, but would become secured if not repaid within three months. Construction Finance Liability On January 28, 2022, a wholly owned subsidiary of the Company acquired property at 29 Everett in conjunction with the NECC Merger (see Note 5 for further details on the transaction). Concurrently, effective January 28, 2022, the Company sold a portion of the property it had acquired in the acquisition for $16 million. In connection with the sale of the property at 29 Everett, the Company agreed to lease the location back for cultivation, effective on January 28, 2022 with available repurchase options. This transaction did not meet the requirements of a sale leaseback transaction and as such was accounted for as a failed sale leaseback. On January 28, 2022, the Company recorded a construction finance liability for the proceeds received from the sale to recognize a liability resulting from the failed sale-leaseback transaction. The initial term of the agreement is 20 years, with two options to extend the term for five years each. The initial monthly rent payment is equal to $0.1 million for the first year of the agreement, with 3% annual increases over the life of the agreement. As of September 30, 2022, the total finance liability associated with this transaction is $16.0 million. The total interest expense incurred during the three and nine months ending September 30, 2022 was $0.4 million and $1.1 million .

Share Capital and Equity

Share Capital and Equity	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Share Capital and Equity	SHARE CAPITAL AND EQUITY The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value. All share classes are included within share capital in the consolidated statements of shareholders’ equity on an as- converted basis. Each share class is entitled to notice of and to attend any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an as-converted basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner. Voting shares activity for the periods presented is summarized as follows: Class A Subordinate Voting Shares Class C Multiple Voting Shares Total Balance, December 31, 2021 592,905,396 1,276,208 594,181,604 Share capital issuances 47,481,290 — 47,481,290 Balance, September 30, 2022 640,386,686 1,276,208 641,662,894 Class A Subordinate Voting Shares Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS. Class C Multiple Voting Shares Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the later of the date that (i) the aggregate number of PVS and MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of PVS and MVS held by the Initial Holders on the date of completion of the Business Combination with Cannex, and (ii) 3 years following the date of the business combination with Cannex. Series Shares outstanding as of September 30, 2022 As converted to SVS Shares Class A - Subordinate Voting Shares 640,386,686 640,386,686 Class C - Multiple Voting Shares 1,276,208 1,276,208 641,662,894 641,662,894 On November 23, 2020, the Company closed a brokered private placement and issued 24,644,500 Units at a price of C$0.70 per Unit. Each Unit is comprised of one subordinate voting share of the Company and one-half of a subordinate voting share purchase warrant. Each whole warrant entitles the holder to purchase one subordinate voting share for a period of two years from the date of issuance at an exercise price of C$0.90 per subordinate voting share. Net proceeds from this transaction were $11.6 million net of share issuance costs of $0.7 million. These warrants meet the criteria in ASC 480, and are therefore classified as derivative liabilities at fair value with changes being reported through the statement of operations. All other warrants detailed in Note 9 did not meet the criteria in ASC480 for liability classification and are classified within equity. 9/30/2022 12/31/2021 Share Price C$0.43 C$1.27 Exercise Price C$0.90 C$0.90 Expected Life 0.2 years 0.9 years Annualized Volatility 0.8294 0.4623 Dividend yield 0 0 Discount Rate 0.0378 0.0039 C$ Exchange Rate 1.37 1.27 The decrease in the value of the derivative liability is reflected in the statement of operations as a $3.5 million and $0.5 million gain on the change in fair value of the derivative liability for the nine months ending September 30, 2022 and 2021. Refer to Note 13

Warrants

Warrants	9 Months Ended
	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	WARRANTS As of September 30, 2022, there were share purchase warrants outstanding to purchase up to 29,103,553 SVS shares: Series Number of warrants Weight-average exercise price Balance, December 31, 2021 26,192,237 $ 0.75 Issued 2,999,975 1.00 Exercised (88,659) 0.56 Balance, September 30, 2022 29,103,553 $ 0.75 As of September 30, 2022, the Company has the following warrants outstanding: Warrants Outstanding Exercise Price Expiration Date 10,403,150 C$ 0.90 * November 23, 2022 209,426 C$ 0.70 * November 23, 2022 12,135,922 $ 0.82* December 17, 2022 2,230,080 $ 0.67* January 29, 2023 2,999,975 $ 1.00 April 13, 2024 625,000 C$ 0.80 * October 6, 2024 500,000 C$ 0.80 * October 6, 2025 29,103,553 *Represents warrants that are exercisable as of September 30, 2022.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the compensation committee of the board of directors but will not be less than 100% of the fair market value of the Company’s shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board. As of September 30, 2022, the Company had the 47,549,343 options exercisable and 57,051,012 options outstanding, with exercise prices ranging from C$0.10 to C$1.63. Stock option activity is summarized as follows: Number of Options Weighted Average Price CAD$ Weighted Average Years Balance December 31, 2021 54,282,752 0.94 2.97 Granted 7,460,000 0.82 3.38 Exercised (51,975) 0.80 0 Forfeited/ Expired (4,639,765) 1.01 0 Balance September 30, 2022 57,051,012 0.89 2.36 During the nine months ended September 30, 2022 and 2021, the Company recognized share-based compensation of $2.3 million and $8.0 million. During the three months ended September 30, 2022 and 2021, the Company recognized share-based compensation of $0.9 million and $2.6 million, respectively. In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish the fair value of options granted during the year with the following key assumptions: 2022 2021 Risk-Free Interest Rate 3.62 % 0.87% to 0.92% Expected Life 3.5 years 5.00 years Expected Annualized Volatility 89.83 % 86.20% to 93.53% Forfeiture rate — % — % Expected Dividend Yield — % — %

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Parties	RELATED PARTIES Related party transactions LI Lending LLC Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to $45.0 million loan from LI Lending of which $48.3 million was outstanding as of December 31, 2021. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28% ownership interest in LI Lending. The loan matures in May 2024. Upon maturity, an exit fee of $9 million is payable, for a total payable at maturity of $54 million. $49.7 million of the loan advanced includes the notes payable and accrued interest less debt discount of $0.3 million that was outstanding as of September 30, 2022. Of the $49.4 million outstanding at September 30, 2022, $5.8 million represents interest accrued through September 30, 2022. See Note 7 for details on the outstanding note payable. Pure Ratios Leonid Gontmakher, Chief Executive Officer of the Company, holds an interest in an entity related to iWolf Management, LLC, an online marketing company serving the online CBD market which provided online marketing services during 2020 and 2019 for the Company’s Pure Ratios division. Pure Ratios paid $0.3 million for the three and nine months ended September 30, 2021 to this vendor for management fees, pass through marketing costs and customer service. Pure Ratios did not make any such payments during the nine months ended September 30, 2022.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES (a) Cannabis Industry While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, there is an inherent risk related to the federal government’s position on cannabis. There is additional risk associated with the Company’s business in cannabis that third-party service providers could suspend or withdraw services and regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S. As of September 30, 2022 , Company has not estimated a potential liability related to the possible enforcement of laws against the medical cannabis industry. (b) Contingent consideration payable As part of the acquisition of Om of Medicine, LLC and Cannex’s prior acquisition of Pure Ratios, the Company is subject to contingent consideration payable to the sellers. The fair value of the contingent consideration, which is based on specific revenue levels achieved over a 2-3-year period, is as follows: Om of Medicine Balance, December 31, 2021 $ 2,393 Changes in fair value (2,393) Balance, September 30, 2022 — Less: current portion — Long-term portion $ — The contingent consideration payable is measured at fair value based on unobservable inputs and is considered a Level 3 financial instrument. The determination of the fair value of these liabilities is primarily driven by the Company’s expectations of the respective subsidiaries achieving certain milestones. The expected milestones were assigned probabilities and the expected related cash flows were discounted to derive the fair value of the contingent consideration. The Company had an outstanding balance of contingent consideration of $2.4 million for the period ended December 31, 2021. However, the Company performed analyses and determined it does not anticipate the subsidiaries to reach the required milestone for the year ended December, 31, 2022. As a result, the Company estimated the contingent consideration to be $0 as of September 30, 2022 and recorded a gain on the fair value adjustment. (c) Legal Matters From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest.

Financial Instruments and Finan

Financial Instruments and Financial Risk Management	9 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Financial Instruments and Financial Risk Management	FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. The Company follows this authoritative guidance for fair value measurements, which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles in the United States of America, and expands disclosures about fair value measurements. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and Level 3 Inputs for the asset or liability that are not based on observable market data (unobservable inputs). Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the periods ended September 30, 2022, and 2021, and December 31, 2021. The fair value of the Company’s cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company’s notes receivable, lease receivables, contingent consideration payable, derivative liabilities, lease liabilities, convertible notes payable, construction finance liability and notes payable approximate fair value due to the instruments bearing market rates of interest or their short term nature. As the interest rates utilized to calculate these instruments approximates market value interest rates, the carrying amounts of the instruments approximate fair value, which are primarily based on Level 1 inputs. The fair value of stock options granted were estimated based on a Black-Scholes model during the periods ended September 30, 2022 and December 31, 2021. The estimated fair value of the derivative liabilities, which represents an embedded put included in the convertible notes payable, represent Level 3 measurements. The following table details the fair value measurements within the fair value hierarchy of the Company's financial instruments, which includes the Level 3 liabilities: Fair value at September 30, 2022 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 8 $ — $ — $ 8 Total liabilities $ 8 $ — $ — $ 8 Fair value at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 3,502 $ — $ — $ 3,502 Total liabilities $ 3,502 $ — $ — $ 3,502 The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3): For the Nine Months Ended September 30, Derivative liability: 2022 2021 Balance, beginning of period $ 3,502 $ 5,807 (Gain) loss on fair value of derivative liability (3,494) (502) Change in fair value of derivative liability upon exercise of warrants — (1,427) Balance, end of period $ 8 $ 3,878 There were no transfers between fair value levels for the nine months ended September 30, 2022 and the year ending December 31, 2021. (a) Financial Risk Management The Company is exposed in varying degrees to a variety of financial instruments related risks. The Company's board of directors mitigate these risks by assessing, monitoring and approving the Company’s risk management processes. (b) Credit Risk Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, accounts receivable, lease receivables, other receivables, and notes receivable. The Company’s maximum credit risk exposure is equivalent to the carrying value of these instruments at the financial statement date. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Lease receivables, notes receivables and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships. The Company maintains cash with federally insured financial institutions. As of December 31, 2021, the Company exceeded federally insured limits by approximately $11 million. The Company did not exceed any federally insured limits at any of its financial institutions as of September 30, 2022. The Company has historically not experienced any losses in such accounts. As of September 30, 2022, the Company held an immaterial amount of cash in a Canadian account that is denominated in C$. As of September 30, 2022 and December 31, 2021, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivable, notes receivable and lease receivables was $18.4 million and $12.7 million, respectively. (c) Liquidity Risk The Company manages liquidity risk through the management of its capital structure. The Company’s approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due. The Company has raised capital as needed, however there is no guarantee the company will be able to continue to raise funds in the same manor it has historically. The Company has the following obligations as of September 30, 2022, which are expected to be payable in the following respective periods: Less than 1 year 1 to 3 years 3 to 5 years Greater than 5 years Total Accounts payable and accrued liabilities $ 22,923 $ 1,200 $ — $ — $ 24,123 Convertible notes, notes payable and accrued interest 9,299 75,214 — — 84,513 Construction finance liability — 16,000 — — 16,000 Total $ 32,222 $ 92,414 $ — $ — $ 124,636 (d) Foreign Exchange Risk The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company’s share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be reduced. The Company also has bank accounts with balances in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in “natural hedging” for funds held in Canada.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION Reportable Segments Operating segments are components of the Company that combine similar business activities, with activities grouped to facilitate the evaluation of business units and allocation of resources by the Company’s board of directors and management. As of September 30, 2022, the Company had two reportable segments: THC Cannabis for the THC cannabis cultivation, manufacturing, and distribution and CBD Wellness which encompasses the Company's CBD sales to third party consumers. The below table presents revenues and net (income) loss by type for the three and nine months ended September 30, 2022 and 2021, as well as assets by type as of September 30, 2022 and December 31, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net Revenues THC Cannabis $ 32,308 $ 25,529 $ 86,286 $ 74,073 CBD Wellness 166 412 675 1,959 Corporate — — — — Total Net Revenues 32,474 25,941 86,961 76,032 Net (Income) Loss attributable to shareholders THC Cannabis (363) 949 3,739 4,790 CBD Wellness (51) 381 (170) 1,201 Corporate 9,020 3,269 17,487 15,920 Total Net Loss $ 8,606 $ 4,599 $ 21,056 $ 21,911 Assets September 30, 2022 December 31, 2021 THC Cannabis $ 318,717 $ 238,933 CBD Wellness 839 805 Corporate 443 15,801 Total Assets $ 319,999 $ 255,539

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The following table summarizes the Company's income tax expense: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Net loss before income taxes $ (5,279) $ (53) $ (11,239) $ (11,351) Income tax expense (3,322) (4,541) (9,802) (10,545) The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. The Company believes the use of this discrete method is more appropriate than the annual effective tax rate method due to the early growth stage of the business. At this time, there is a high degree of uncertainty in estimating the Company’s annual pre-tax income and significant non-deductible expenses so the Company cannot reliably estimate the annual effective tax rate. Due to its cannabis operations, the Company is subject to the limitations of Internal Revenue Code (“IRC”) Section 280E. Under IRC Section 280E, the Company is only allowed to deduct expenses directly related to sales of its cannabis products. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E for the Company's expenses related to its plant-touching cannabis operations. The federal statute of limitation remains open for the 2018 tax year to the present. The state income tax returns generally remain open for the 2017 tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS On October 13, 2022, the Company entered into a Prepaid Forward Purchase Agreement with Frisco SPV, LLC. Under the terms of the agreement, Frisco SPV, LLC agreed to advance the Company $3.75 million in exchange for a share of the proceeds of the Company’s planned litigation against four former licensing clients. The funder’s share is equal to 1.5 multiplied by the amount of the advance, plus 35 percent of the proceeds of the litigation after deducting the funder’s multiple return, plus, beginning October 2024, 15% interest on the advance, if not repaid sooner. On October 21 and 25, 2022, Frisco SPV, LLC completed the funding as agreed. The funding is unsecured and non-recourse in the event the Company is unsuccessful in these proceedings. On October 27, 2022, Company subsidiary IL Grown Medicine LLC entered into a First Amendment to Lease Agreement amending its lease with IIP-IL 6 LLC for the Company’s Matteson, Illinois facility by creating an option for IL Grown to increase the tenant improvement allowance for the facility by between $15.0 million and $19.9 million. On November 10, 2022, IL Grown exercised its option and entered into a Second Amendment to Lease Agreement increasing the tenant improvement allowance under the lease by $19.9 million; extending the term of the lease to 20 years after the amendment; increasing the base rent by $0.2 million per month (abated until April 1, 2023); and increasing the security deposit by $2.2 million, to be funded pro rata out of draws on the tenant improvement allowance.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Accounting Standard Updates Issued but Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurements - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Summary of Inventory	The Company’s inventories include the following as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 Raw materials - unharvested cannabis $ 4,584 $ 2,164 Raw materials - harvested and purchased cannabis 12,425 3,045 Packaging and other non-finished goods 3,547 1,734 Work in process - manufactured and purchased extracts 2,124 4,771 Finished goods 8,256 8,373 Total $ 30,936 $ 20,087

Property Plant and Equipment (T

Property Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment and Related Depreciation	Property, plant and equipment and related depreciation are summarized in the table below: September 30, 2022 December 31, 2021 Land $ 775 $ — Buildings & improvements 14,253 1,483 Construction in process 328 63 Furniture, equipment & other 19,422 13,425 Leasehold improvements 36,623 35,538 Total $ 71,401 $ 50,509 Less: accumulated depreciation (12,704) (7,876) Total property, plant, and equipment, net $ 58,697 $ 42,633

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Intangible assets and related amortization are summarized in the table below: Licenses Customer Relationships Non-Competition Agreements Know-How Tradenames and Trademarks Total Balance, December 31, 2021 $ 20,146 $ 1,088 $ — $ 5,012 $ — $ 26,246 Acquisitions (Note 5) 26,700 — — — 3,522 30,222 Amortization expense — (437) — (1,455) (124) (2,016) Balance, September 30, 2022 $ 46,846 $ 651 $ — $ 3,557 $ 3,398 $ 54,452
Schedule of Finite-Lived Intangible Assets	Intangible assets and related amortization are summarized in the table below: Licenses Customer Relationships Non-Competition Agreements Know-How Tradenames and Trademarks Total Balance, December 31, 2021 $ 20,146 $ 1,088 $ — $ 5,012 $ — $ 26,246 Acquisitions (Note 5) 26,700 — — — 3,522 30,222 Amortization expense — (437) — (1,455) (124) (2,016) Balance, September 30, 2022 $ 46,846 $ 651 $ — $ 3,557 $ 3,398 $ 54,452
Summary of Goodwill	Goodwill Balance, December 31, 2021 $ 23,155 Acquisitions (Note 5) 18,238 Balance, September 30, 2022 $ 41,393

Acquisitions and Business Com_2

Acquisitions and Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Summary of the Preliminary Purchase Price Allocation Finalized for the NECC Acquisition	The following tables present the preliminary purchase price allocation for the NECC Merger: Cash consideration $ 25,000 Note to seller 2,000 Equity consideration - common stock 18,200 Total Purchase Price $ 45,200 Description Fair value Assets acquired: Cash $ 2 Inventory 213 Prepaid assets 2 Property, plant, and equipment 16,000 Intangible asset - licenses 18,000 Total assets acquired $ 34,217 Liabilities assumed: Accounts payable 800 Total liabilities assumed $ 800 Estimated fair value of net assets acquired $ 33,417 Estimated Goodwill $ 11,783 The following tables present the preliminary purchase price allocation for the Island Merger: Note to seller $ 10,000 Equity consideration - common stock 6,245 Equity consideration - warrants 732 Total Purchase Price $ 16,977 Description Fair value Assets acquired: Cash $ 458 Accounts receivable 511 Inventory 3,072 Prepaid expenses and other current assets 424 Property and equipment, net 2,214 Operating lease - right of use asset 10,227 Intangible assets 11,300 Total assets acquired $ 28,206 Liabilities assumed: Accounts payable $ 1,356 Accrued expenses and other liabilities 2,566 Contract liabilities 3,535 Lease liabilities 10,227 Total liabilities assumed 17,684 Estimated fair value of net assets acquired $ 10,522 Estimated Goodwill $ 6,455
Summary of Asset Acquisition	Share Consideration $ 2,100 Transaction Costs 6 Total Purchase Price $ 2,106 The allocation of the asset acquisition cost is detailed below: Description Fair Value Assets acquired: Accounts receivable $ 508 Inventory 534 Equipment 142 Intangible assets - tradenames 922 Total assets acquired $ 2,106
Summary of Pro Forma Information	The unaudited pro forma financial information for the Company including NECC and Island is as follows: For the For the Three Months Ended September 30, 2022 2021 Reported Proforma Reported Proforma Revenues $ 32,474 $ 32,474 $ 25,941 $ 28,238 (Loss) income from operations 517 517 (924) (2,603) Net loss $ (8,601) $ (8,601) $ (4,594) $ (8,103) Basic and diluted earning (loss) per share $ (0.01) $ (0.01) $ (0.01) $ (0.01) For the For the Nine Months Ended September 30, 2022 2021 Reported Proforma Reported Proforma Revenues $ 86,961 $ 88,689 $ 76,032 $ 81,524 (Loss) income from operations (4,823) (5,875) 97 (5,093) Net loss $ (21,041) $ (27,235) $ (21,896) $ (28,916) Basic and diluted earning (loss) per share $ (0.03) $ (0.04) $ (0.04) $ (0.05)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Summary of Changes in Lease Receivables	The following table summarizes changes in the Company’s lease receivables: September 30, 2022 December 31, 2021 Balance, beginning of the year $ 10,378 $ 11,045 Interest 2,029 2,783 Lease payments received (2,700) (3,450) Balance, end of the period 9,707 $ 10,378 Less current portion (3,765) (3,630) Long-term lease receivables $ 5,942 $ 6,748

Notes Payable and Convertible_2

Notes Payable and Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Summary of Notes Payable and Convertible Notes	The Company’s notes payable and convertible notes are as follows: LI Lending, LLC May 2020 Convertible Notes May 2020 Convertible Notes (Swap) October 2021 Convertible Note Other Loans Total Balance, December 31, 2020 $ 45,362 $ 2,855 $ 11,867 $ — $ 6,931 $ 67,015 Loans advanced, net — — — 14,376 930 15,306 Loan payments (4,671) — — — (1,079) (5,750) Converted to equity — (5,852) (11,867) — — (17,719) Accrued interest 7,575 2,997 — 265 1,124 11,961 Balance, December 31, 2021 $ 48,266 $ — $ — $ 14,641 $ 7,906 $ 70,813 Loans advanced, net — — — — 15,000 15,000 Loan payments (4,689) — — — (1,182) (5,871) Converted to equity — — — — (2,784) (2,784) Accrued interest 5,845 — — 872 638 7,355 Balance, September 30, 2022 $ 49,422 $ — $ — $ 15,513 $ 19,578 $ 84,513 Less current portion — — — — (9,299) (9,299) Long-term portion $ 49,422 $ — $ — $ 15,513 $ 10,279 $ 75,214
Summary of Convertible Debt	Outstanding as of September 30, 2022 were other payables totaling $19.6 million which include notes issued as part of the acquisitions of Healthy Pharms, NECC, Island, and Arkansas entities as follows: Subsidiary Terms September 30, 2022 December 31, 2021 Healthy Pharms Inc. Unsecured convertible note, due November 18, 2021 at 12% per annum $ — $ 2,784 Healthy Pharms Inc. Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1) 3,463 3,213 Island Global Holdings, Inc. Promissory note due October 25, 2026 at 6% per annum 10,279 — NECC Promissory note due November 15, 2022 at 10% per annum (2) 1,005 — Island Global Holdings, Inc. Promissory note due February 28, 2023 at 1.5% per month (3) 3,057 — Arkansas Entities Unsecured Promissory note due December 1,2022, monthly interest payments at 14% per annum 1,730 1,709 Equipment Loans Secured by equipment, monthly payments beginning in 2021 at 15% per annum 44 49 Other Various — 151 Total Notes Payable and Convertible Notes $ 19,578 $ 7,906 (1) In November 2021, the unsecured promissory note was modified to be due and payable in full on or before December 18, 2022. The Company concluded the extension resulted in a debt modification under ASC 470 . (2) On July 28, 2022, the parties amended the promissory note to provide for payment of half the principal on the initial maturity date, and the remaining principal and all accrued interest on November 15, 2022. Interest will continue at annual rate of ten percent (10%). (3) On August 30, 2022, the Company entered into a Promissory Note Purchase Agreement with HI 4Front, LCC and Navy Capital Green Fund, LP. Under the agreement, the Company sold promissory notes totaling $3 million with a six-month maturity bearing 1.5% monthly interest for three months and 2% monthly interest for three months. The notes were unsecured, but would become secured if not repaid within three months.

Share Capital and Equity (Table

Share Capital and Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Summary of Voting Shares Activity	Voting shares activity for the periods presented is summarized as follows: Class A Subordinate Voting Shares Class C Multiple Voting Shares Total Balance, December 31, 2021 592,905,396 1,276,208 594,181,604 Share capital issuances 47,481,290 — 47,481,290 Balance, September 30, 2022 640,386,686 1,276,208 641,662,894
Summary of Share Capital and Equity	Series Shares outstanding as of September 30, 2022 As converted to SVS Shares Class A - Subordinate Voting Shares 640,386,686 640,386,686 Class C - Multiple Voting Shares 1,276,208 1,276,208 641,662,894 641,662,894
Summary of Measurement Input Valuation Techniques	9/30/2022 12/31/2021 Share Price C$0.43 C$1.27 Exercise Price C$0.90 C$0.90 Expected Life 0.2 years 0.9 years Annualized Volatility 0.8294 0.4623 Dividend yield 0 0 Discount Rate 0.0378 0.0039 C$ Exchange Rate 1.37 1.27

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Outstanding to Purchase Shares	As of September 30, 2022, there were share purchase warrants outstanding to purchase up to 29,103,553 SVS shares: Series Number of warrants Weight-average exercise price Balance, December 31, 2021 26,192,237 $ 0.75 Issued 2,999,975 1.00 Exercised (88,659) 0.56 Balance, September 30, 2022 29,103,553 $ 0.75
Summary of Warrants Outstanding And Exercisable	As of September 30, 2022, the Company has the following warrants outstanding: Warrants Outstanding Exercise Price Expiration Date 10,403,150 C$ 0.90 * November 23, 2022 209,426 C$ 0.70 * November 23, 2022 12,135,922 $ 0.82* December 17, 2022 2,230,080 $ 0.67* January 29, 2023 2,999,975 $ 1.00 April 13, 2024 625,000 C$ 0.80 * October 6, 2024 500,000 C$ 0.80 * October 6, 2025 29,103,553 *Represents warrants that are exercisable as of September 30, 2022.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	Stock option activity is summarized as follows: Number of Options Weighted Average Price CAD$ Weighted Average Years Balance December 31, 2021 54,282,752 0.94 2.97 Granted 7,460,000 0.82 3.38 Exercised (51,975) 0.80 0 Forfeited/ Expired (4,639,765) 1.01 0 Balance September 30, 2022 57,051,012 0.89 2.36
Summary of Stock Options Values using Black-Scholes Model with Key Assumptions	In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish the fair value of options granted during the year with the following key assumptions: 2022 2021 Risk-Free Interest Rate 3.62 % 0.87% to 0.92% Expected Life 3.5 years 5.00 years Expected Annualized Volatility 89.83 % 86.20% to 93.53% Forfeiture rate — % — % Expected Dividend Yield — % — %

Contingencies (Tables)

Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Fair Value of Contingent Consideration	The fair value of the contingent consideration, which is based on specific revenue levels achieved over a 2-3-year period, is as follows: Om of Medicine Balance, December 31, 2021 $ 2,393 Changes in fair value (2,393) Balance, September 30, 2022 — Less: current portion — Long-term portion $ —

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Schedule of Fair Value Measurements With in the Fair Value Hierarchy of The Financial Instruments	The guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and Level 3 Inputs for the asset or liability that are not based on observable market data (unobservable inputs). The following table details the fair value measurements within the fair value hierarchy of the Company's financial instruments, which includes the Level 3 liabilities: Fair value at September 30, 2022 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 8 $ — $ — $ 8 Total liabilities $ 8 $ — $ — $ 8 Fair value at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 3,502 $ — $ — $ 3,502 Total liabilities $ 3,502 $ — $ — $ 3,502
Summary of Changes in Fair Value of the Derivative Liabilities Measured on a Recurring Basis	The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3): For the Nine Months Ended September 30, Derivative liability: 2022 2021 Balance, beginning of period $ 3,502 $ 5,807 (Gain) loss on fair value of derivative liability (3,494) (502) Change in fair value of derivative liability upon exercise of warrants — (1,427) Balance, end of period $ 8 $ 3,878
Schedule of Gross Contractual Obligations	The Company has the following obligations as of September 30, 2022, which are expected to be payable in the following respective periods: Less than 1 year 1 to 3 years 3 to 5 years Greater than 5 years Total Accounts payable and accrued liabilities $ 22,923 $ 1,200 $ — $ — $ 24,123 Convertible notes, notes payable and accrued interest 9,299 75,214 — — 84,513 Construction finance liability — 16,000 — — 16,000 Total $ 32,222 $ 92,414 $ — $ — $ 124,636

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Revenue By Type	The below table presents revenues and net (income) loss by type for the three and nine months ended September 30, 2022 and 2021, as well as assets by type as of September 30, 2022 and December 31, 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net Revenues THC Cannabis $ 32,308 $ 25,529 $ 86,286 $ 74,073 CBD Wellness 166 412 675 1,959 Corporate — — — — Total Net Revenues 32,474 25,941 86,961 76,032 Net (Income) Loss attributable to shareholders THC Cannabis (363) 949 3,739 4,790 CBD Wellness (51) 381 (170) 1,201 Corporate 9,020 3,269 17,487 15,920 Total Net Loss $ 8,606 $ 4,599 $ 21,056 $ 21,911 Assets September 30, 2022 December 31, 2021 THC Cannabis $ 318,717 $ 238,933 CBD Wellness 839 805 Corporate 443 15,801 Total Assets $ 319,999 $ 255,539

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Summary of Income Tax Expense and Effective Tax Rates	The following table summarizes the Company's income tax expense: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Net loss before income taxes $ (5,279) $ (53) $ (11,239) $ (11,351) Income tax expense (3,322) (4,541) (9,802) (10,545)

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) Segment Dispensary facility	Dec. 31, 2021 USD ($)
Nature Of Operations [Line Items]
Number of operating segments | Segment	2
Number of dispensaries | Dispensary	6
Contract liabilities	$ 2,700
Current portion of contract liabilities	653	$ 0
Non-current contract liabilities	$ 2,000	$ 0
Illinois, Michigan, Massachusetts, and California
Nature Of Operations [Line Items]
Number of production facilities | facility	9

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Packaging and other non-finished goods	$ 3,547	$ 1,734
Work in process - manufactured and purchased extracts	2,124	4,771
Finished goods	8,256	8,373
Total	30,936	20,087
Raw materials - unharvested cannabis
Inventory [Line Items]
Raw materials	4,584	2,164
Raw materials - harvested and purchased cannabis
Inventory [Line Items]
Raw materials	$ 12,425	$ 3,045

Property Plant and Equipment -

Property Plant and Equipment - Summary of Property and Equipment and Related Depreciation (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 71,401	$ 50,509
Less: accumulated depreciation	(12,704)	(7,876)
Total property, plant, and equipment, net	58,697	42,633
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	775	0
Buildings & improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	14,253	1,483
Construction in process
Property, Plant and Equipment [Line Items]
Property and equipment, gross	328	63
Furniture, equipment & other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,422	13,425
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 36,623	$ 35,538

Property Plant and Equipment _2

Property Plant and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, net	$ 58,697,000		$ 58,697,000		$ 42,633,000
Contractual commitments for future capital expenditures	0		0		$ 0
Depreciation expense	1,400,000	$ 700,000	4,800,000	$ 1,800,000
Depreciation in COGS	1,200,000	$ 500,000	3,900,000	$ 1,200,000
Asset Pledged as Collateral
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, net	$ 33,000,000		$ 33,000,000

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Indefinite-Lived and Finite-Lived Intangible Assets (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Finite-Lived Intangible Assets [Roll Forward]
Amortization expense	$ (2,016)
Total
Balance, December 31, 2021	26,246
Acquisitions (Note 5)	30,222
Balance, September 30, 2022	54,452
Licenses
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	20,146
Acquisitions	26,700
Ending balance	46,846
Customer Relationships
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	1,088
Acquisitions	0
Amortization expense	(437)
Ending balance	651
Non-Competition Agreements
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	0
Acquisitions	0
Amortization expense	0
Ending balance	0
Know-How
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	5,012
Acquisitions	0
Amortization expense	(1,455)
Ending balance	3,557
Tradenames and Trademarks
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	0
Acquisitions	3,522
Amortization expense	(124)
Ending balance	$ 3,398

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Summary of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 23,155
Acquisitions	18,238
Ending balance	$ 41,393

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Additional Information (Details) $ in Millions	Sep. 30, 2022 USD ($)
CBD Wellness
Disclosure Of Intangible Assets And Goodwill [Line Items]
Accumulated impairment	$ 13.4

Acquisitions And Business Com_3

Acquisitions And Business Combinations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended	9 Months Ended
	Aug. 19, 2022	Apr. 25, 2022	Jan. 28, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Business combination consideration transferred liabilities incurred		$ 10,000
Warrants (in shares)				29,103,553	29,103,553	26,192,237
Bloom Farms
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Asset acquisition, consideration transferred, equity interest value	$ 2,100
Asset acquisition, consideration transferred, transaction cost	6
Asset acquisition, contingent consideration, revenue threshold amount	2,100
Bloom Farms | Maximum
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Asset acquisition, contingent consideration, liability	$ 5,000
Subordinate Voting Share | Bloom Farms
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Asset acquisition, stock consideration (in shares)	3,750,000
Asset acquisition, consideration transferred, equity interest value	$ 2,100
Asset acquisition, consideration transferred, transaction cost	$ 60
New England Cannabis Corporation
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Percentage of voting interests acquired			100%
Cash consideration			$ 9,000		$ 25,000
Business combination consideration transferred liabilities incurred					2,000
Transaction and restructuring costs					700
New England Cannabis Corporation | Subordinate Voting Share
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Number of shares issued as a settlement of consideration (in shares)			28,600,000
29 Everett Street LLC
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Percentage of voting interests acquired			100%
Cash consideration			$ 16,000
Business combination consideration transferred liabilities incurred			$ 2,000
Island Global Holdings, Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Percentage of voting interests acquired		100%
Business combination consideration transferred liabilities incurred		$ 10,000
Transaction and restructuring costs					$ 1,300
Interest rate, stated percentage		6%
Debt instrument, term		54 months
Island Global Holdings, Inc. | Trademarks and Trade Names
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Acquired indefinite-lived intangible assets, useful life					10 years
Island Global Holdings, Inc. | Subordinate Voting Share
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Warrants (in shares)		2,999,975
Warrants purchase price per share (in dollar per share)		$ 1
Island Global Holdings, Inc. | Subordinate Voting Share
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Number of shares issued as a settlement of consideration (in shares)		8,783,716
New England Cannabis Corporation and Island Global Holdings Inc.
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Acquisition-related revenue				$ 2,500	$ 3,500
Acquisition-related net income (loss)				$ 1,800	$ (100)

Acquisitions and Business Com_4

Acquisitions and Business Combinations - Summary Of The Preliminary Purchase Price Allocation Finalized For The NECC Acquisition (Details) - USD ($) $ in Thousands			9 Months Ended
	Apr. 25, 2022	Jan. 28, 2022	Sep. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Note to seller	$ 10,000
Liabilities assumed:
Estimated Goodwill			$ 41,393	$ 23,155
New England Cannabis Corporation
Business Acquisition [Line Items]
Cash consideration		$ 9,000	25,000
Note to seller			2,000
Equity consideration - common stock			18,200
Total Purchase Price			$ 45,200
Assets acquired:
Cash		2
Inventory		213
Prepaid expenses and other current assets		2
Property, plant, and equipment		16,000
Intangible assets		18,000
Total assets acquired		34,217
Liabilities assumed:
Accounts payable		800
Total liabilities assumed		800
Estimated fair value of net assets acquired		33,417
Estimated Goodwill		$ 11,783
Island Global Holdings, Inc.
Business Acquisition [Line Items]
Note to seller	10,000
Equity consideration - common stock	6,245
Equity consideration - warrants	732
Total Purchase Price	16,977
Assets acquired:
Cash	458
Accounts receivable	511
Inventory	3,072
Prepaid expenses and other current assets	424
Property, plant, and equipment	2,214
Operating lease - right of use asset	10,227
Intangible assets	11,300
Total assets acquired	28,206
Liabilities assumed:
Accounts payable	1,356
Accrued expenses and other liabilities	2,566
Contract liabilities	3,535
Lease liabilities	10,227
Total liabilities assumed	17,684
Estimated fair value of net assets acquired	10,522
Estimated Goodwill	$ 6,455

Acquisitions and Business Com_5

Acquisitions and Business Combinations - Summary of Asset Acquisition (Details) - Bloom Farms $ in Thousands	Aug. 19, 2022 USD ($)
Asset Acquisition [Line Items]
Share Consideration	$ 2,100
Transaction Costs	6
Total Purchase Price	2,106
Assets acquired:
Accounts receivable	508
Inventory	534
Equipment	142
Intangible assets - tradenames	922
Total assets acquired	$ 2,106

Acquisitions and Business Com_6

Acquisitions and Business Combinations - Summary Of Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Reported
Revenues	$ 32,474			$ 25,941			$ 86,961	$ 76,032
(Loss) income from operations	517			(924)			(4,823)	97
Net loss	$ (8,601)	$ (6,546)	$ (5,894)	$ (4,594)	$ (6,218)	$ (11,084)	$ (21,041)	$ (21,896)
Basic loss per share (in dollar per share)	$ (0.01)			$ (0.01)			$ (0.03)	$ (0.04)
Diluted loss per share (in dollar per share)	$ (0.01)			$ (0.01)			$ (0.03)	$ (0.04)
Proforma
Revenues	$ 32,474			$ 28,238			$ 88,689	$ 81,524
(Loss) income from operations	517			(2,603)			(5,875)	(5,093)
Net loss	$ (8,601)			$ (8,103)			$ (27,235)	$ (28,916)
Basic earning (loss) per share (in dollar per share)	$ (0.01)			$ (0.01)			$ (0.04)	$ (0.05)
Diluted earning (loss) per share (in dollar per share)	$ (0.01)			$ (0.01)			$ (0.04)	$ (0.05)

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Leases [Line Items]
Long term lease receivable	$ 5,942		$ 5,942		$ 6,748
Current portion of lease receivables	3,765		3,765		$ 3,630
Real estate income	3,407	$ 2,815	9,323	$ 8,374
Sublease income			500
Elma, Building
Leases [Line Items]
Real estate income	600	700	2,000	2,100
Olympia Building
Leases [Line Items]
Real estate income	$ 2,300	$ 2,100	$ 6,800	$ 6,300

Leases - Summary of Changes in

Leases - Summary of Changes in Lease Receivables (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Sales-type and Direct Financing Leases, Lease Receivable [Roll Forward]
Balance, beginning of the year	$ 10,378	$ 11,045
Interest	2,029	2,783
Lease payments received	(2,700)	(3,450)
Balance, end of the period	9,707	10,378
Less current portion	(3,765)	(3,630)
Long-term lease receivables	$ 5,942	$ 6,748

Notes Payable and Convertible_3

Notes Payable and Convertible Notes - Summary of Notes Payable and Convertible Notes (Details) - USD ($)			3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 06, 2021	May 14, 2020	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument, Increase (Decrease) [Roll Forward]
Beginning Balance				$ 70,813,000	$ 67,015,000
Loans advanced, net				15,000,000	15,306,000
Loan payments				(5,871,000)	(5,750,000)
Converted to equity				(2,784,000)	(17,719,000)
Accrued interest				7,355,000	11,961,000
Ending Balance			$ 84,513,000	84,513,000	70,813,000
Less current portion			(9,299,000)	(9,299,000)
Long-term portion			75,214,000	75,214,000
LI Lending, LLC
Debt Instrument, Increase (Decrease) [Roll Forward]
Beginning Balance				48,266,000	45,362,000
Loans advanced, net				0	0
Loan payments				(4,689,000)	(4,671,000)
Converted to equity				0	0
Accrued interest			2,500,000	5,845,000	7,575,000
Ending Balance			49,422,000	49,422,000	48,266,000
Less current portion			0	0
Long-term portion			49,422,000	49,422,000
May 2020 Convertible Notes | Convertible Note
Debt Instrument, Increase (Decrease) [Roll Forward]
Beginning Balance				0	2,855,000
Loans advanced, net		$ 5,800,000		0	0
Loan payments				0	0
Converted to equity				0	(5,852,000)
Accrued interest				0	2,997,000
Ending Balance			0	0	0
Less current portion			0	0
Long-term portion			0	0
May 2020 Convertible Notes (Swap) | Convertible Note
Debt Instrument, Increase (Decrease) [Roll Forward]
Beginning Balance				0	11,867,000
Loans advanced, net				0	0
Loan payments				0	0
Converted to equity				0	(11,867,000)
Accrued interest				0	0
Ending Balance			0	0	0
Less current portion			0	0
Long-term portion			0	0
October 2021 Convertible Note | Convertible Note
Debt Instrument, Increase (Decrease) [Roll Forward]
Beginning Balance				14,641,000	0
Loans advanced, net	$ 14,400,000			0	14,376,000
Loan payments	$ 0			0	0
Converted to equity				0	0
Accrued interest				872,000	265,000
Ending Balance			15,513,000	15,513,000	14,641,000
Less current portion			0	0
Long-term portion			15,513,000	15,513,000
Other Loans
Debt Instrument, Increase (Decrease) [Roll Forward]
Beginning Balance				7,906,000	6,931,000
Loans advanced, net				15,000,000	930,000
Loan payments				(1,182,000)	(1,079,000)
Converted to equity				(2,784,000)	0
Accrued interest				638,000	1,124,000
Ending Balance			19,578,000	19,578,000	$ 7,906,000
Less current portion			(9,299,000)	(9,299,000)
Long-term portion			$ 10,279,000	$ 10,279,000

Notes Payable and Convertible_4

Notes Payable and Convertible Notes - Convertible Notes Additional Information (Details)				9 Months Ended	12 Months Ended
	Oct. 06, 2021 USD ($) $ / shares	May 28, 2020 USD ($) d $ / shares shares	May 14, 2020 USD ($) d $ / shares	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Loans advanced, net				$ 15,000,000	$ 15,306,000
Repayments of debt				5,871,000	5,750,000
May 2020 Convertible Notes | Convertible Note
Debt Instrument [Line Items]
Loans advanced, net			$ 5,800,000	0	0
Interest rate, stated percentage			5%
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares			$ 0.25
Debt instrument, convertible, stock price trigger (in dollars per share) | $ / shares			$ 0.50
Debt instrument, convertible, threshold consecutive trading days | d			45
Repayments of debt				0	0
May 2020 Convertible Notes (Swap) | Convertible Note
Debt Instrument [Line Items]
Loans advanced, net				0	0
Interest rate, stated percentage		3%
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares		$ 0.46
Debt instrument, convertible, stock price trigger (in dollars per share) | $ / shares		$ 0.92
Debt instrument, convertible, threshold consecutive trading days | d		45
Number of shares exchanged in debt (in shares) | shares		29,448,468
Exchanged shares value		$ 13,700,000
Issued debt in exchange of convertible equity		13,700,000
Minimum required annual revenue for interest payment		$ 15,000,000
Repayments of debt				0	0
October 2021 Convertible Note | Convertible Note
Debt Instrument [Line Items]
Loans advanced, net	$ 14,400,000			0	14,376,000
Interest rate, stated percentage	6%
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares	$ 1.03
Debt instrument, face amount	$ 15,000,000
Payments of debt issuance costs	600,000
Repayments of debt	$ 0			$ 0	$ 0

Notes Payable and Convertible_5

Notes Payable and Convertible Notes - LI Lending LLC Additional Information (Details) $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2022 USD ($) draw	Sep. 30, 2022 USD ($) draw	Dec. 31, 2021 USD ($)	Jan. 01, 2022	May 10, 2019 USD ($)
Debt Instrument [Line Items]
Debt, net amount		$ 67,015	$ 84,513	$ 84,513	$ 70,813
Accrued interest				7,355	11,961
Repayments of debt				5,871	5,750
LI Lending, LLC
Debt Instrument [Line Items]
Maximum borrowing capacity under credit facility							$ 50,000
Amount drawn			$ 45,000	$ 45,000
Number of draws made | draw			2	2
Long-term debt, gross			$ 49,700	$ 49,700
Debt instrument, unamortized discount			300	300
Debt, net amount		$ 45,362	49,422	$ 49,422	48,266
Periodic payment, principal	$ 300
Periodic payment, principal, payment term	8 months
Increase in interest rate		2.50%
Percentage of exit fee of the principal balance				20%
Interest payable			5,800	$ 5,800
Accrued interest			2,500	5,845	7,575
Loan discount accretion expense			40	200
Repayments of debt				4,689	$ 4,671
LI Lending, LLC | LI Lending Facility, Draw One
Debt Instrument [Line Items]
Amount drawn	$ 33,000		$ 35,000	$ 35,000
Interest rate			10.25%	10.25%
Debt prepayment	$ 2,000
Interest rate on initial loan amount						12.75%
LI Lending, LLC | LI Lending Facility, Draw Two
Debt Instrument [Line Items]
Amount drawn			$ 10,000	$ 10,000
Interest rate			12.25%	12.25%
Interest rate on final loan amount						14.75%

Notes Payable and Convertible_6

Notes Payable and Convertible Notes - Summary of Convertible Debt (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Aug. 30, 2022	Feb. 28, 2023	Nov. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Notes payable and convertible notes				$ 19,578	$ 7,906
Healthy Pharms Inc. | Unsecured convertible note, due November 18, 2021 at 12% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage				12%
Notes payable and convertible notes				$ 0	2,784
Healthy Pharms Inc. | Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage				10%
Debt instrument, convertible, conversion price (in dollars per share)				$ 0.50
Notes payable and convertible notes				$ 3,463	3,213
Island Global Holdings, Inc. | Promissory note due October 25, 2026 at 6% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage				6%
Notes payable and convertible notes				$ 10,279	0
Island Global Holdings, Inc. | Promissory note due February 28, 2023 at 1.5% per month
Debt Instrument [Line Items]
Interest rate, stated percentage				1.50%
Notes payable and convertible notes				$ 3,057	0
Proceeds from sale of notes receivable	$ 3,000
Debt instrument, term	6 months
Island Global Holdings, Inc. | Promissory note due February 28, 2023 at 1.5% per month | Forecast
Debt Instrument [Line Items]
Debt instrument, interest rate during period		2%	1.50%
NECC | Promissory note due November 15, 2022 at 10% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage				10%
Notes payable and convertible notes				$ 1,005	0
Arkansas Entities | Unsecured Promissory note due December 1,2022, monthly interest payments at 14% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage				14%
Notes payable and convertible notes				$ 1,730	1,709
Equipment Loans | Secured by equipment, monthly payments beginning in 2021 at 15% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage				15%
Notes payable and convertible notes				$ 44	49
Other | Various
Debt Instrument [Line Items]
Notes payable and convertible notes				$ 0	$ 151

Notes Payable and Convertible_7

Notes Payable and Convertible Notes - Construction Finance Liability (Details) $ in Millions		3 Months Ended	9 Months Ended
	Jan. 28, 2022 USD ($) extensionOption	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Proceeds from sale of property	$ 16
Finance liability, term of contract	20 years
Finance liability, number of extension options | extensionOption	2
Finance liability, renewal term	5 years
Finance liability, monthly payment amount	$ 0.1
Finance liability, payment amount, annual increase percentage	3%
Finance liability		$ 16	$ 16
Accrued interest		$ 0.4	$ 1.1

Share Capital and Equity - Addi

Share Capital and Equity - Additional Information (Details) $ in Thousands		3 Months Ended		9 Months Ended
	Nov. 23, 2020 USD ($) shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) vote shares	Sep. 30, 2021 USD ($)	Nov. 23, 2020 $ / shares
Class Of Stock [Line Items]
Period when the convertibility of shares from one class to another become exercisable				3 years
Share capital issuances (in shares)				47,481,290
Change in fair value of derivative liability | $		$ 420	$ 3,345	$ 3,494	$ 502
Private Placement
Class Of Stock [Line Items]
Number of voting shares in each unit (in shares)		1		1
Number of warrants in each unit (in shares)		0.5		0.5
Number of securities called by each warrant (in shares)		1		1
Warrant term		2 years		2 years
Warrants purchase price per share (in dollar per share) | $ / shares						$ 0.90
Net proceeds from issuance of stock with warrants | $	$ 11,600
Payments of share issuance costs | $	$ 700
Private Placement | Share Capital with Unit Price
Class Of Stock [Line Items]
Share capital issuances (in shares)	24,644,500
Units issued, price per unit (in dollar per share) | $ / shares						$ 0.70
Class C Multiple Voting Shares
Class Of Stock [Line Items]
Number of votes each shareholder is entitled to for each share | vote				800
Percentage of shares of one class held as a percentage of shares of another class		50%		50%
Share capital issuances (in shares)				0

Share Capital and Equity - Summ

Share Capital and Equity - Summary of Voting Shares Activity (Details)	9 Months Ended
	Sep. 30, 2022 shares
Class Of Stock [Line Items]
Beginning balance (in shares)	594,181,604
Share capital issuances (in shares)	47,481,290
Ending balance (in shares)	641,662,894
Class A Subordinate Voting Shares
Class Of Stock [Line Items]
Beginning balance (in shares)	592,905,396
Share capital issuances (in shares)	47,481,290
Ending balance (in shares)	640,386,686
Class C Multiple Voting Shares
Class Of Stock [Line Items]
Beginning balance (in shares)	1,276,208
Share capital issuances (in shares)	0
Ending balance (in shares)	1,276,208

Share Capital and Equity - Su_2

Share Capital and Equity - Summary of Share Capital and Equity (Details) - shares	Sep. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	641,662,894	594,181,604
Class A Shares
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	640,386,686
Class C Shares
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	1,276,208
Class A Subordinate Voting Shares
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	640,386,686	592,905,396
Class C Multiple Voting Shares
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	1,276,208	1,276,208

Share Capital and Equity - Su_3

Share Capital and Equity - Summary of Measurement Input Valuation Techniques (Details) - Option Pricing Model	Sep. 30, 2022 $ / shares yr	Dec. 31, 2021 $ / shares yr
Share Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.43	1.27
Exercise Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.90	0.90
Expected Life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input | yr	0.2	0.9
Annualized Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.8294	0.4623
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0	0
Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.0378	0.0039
C$ Exchange Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	1.37	1.27

Warrants - Summary of Warrants

Warrants - Summary of Warrants Outstanding to Purchase Shares (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Number of warrants
Number of warrants, beginning balance (in shares) | shares	26,192,237
Number of warrants, issued (in shares) | shares	2,999,975
Number of warrants, exercised (in shares) | shares	(88,659)
Number of warrants, ending balance (in shares) | shares	29,103,553
Weight-average exercise price
Weighted average exercise price, Beginning balance (in dollars per share) | $ / shares	$ 0.75
Weighted average exercise price, Issued (in dollars per share) | $ / shares	1
Weighted average exercise price, Exercised (in dollars per share) | $ / shares	0.56
Weighted average exercise price, Ending balance (in dollars per share) | $ / shares	$ 0.75

Warrants - Summary of Warrant_2

Warrants - Summary of Warrants Outstanding And Exercisable (Details)	Sep. 30, 2022 $ / shares shares	Sep. 30, 2022 $ / shares shares	Dec. 31, 2021 shares
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	29,103,553	29,103,553	26,192,237
Exercise Price CAD 0.90
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	10,403,150	10,403,150
Exercise price (in dollar per share) | $ / shares		$ 0.90
Exercise Price CAD 0.70
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	209,426	209,426
Exercise price (in dollar per share) | $ / shares		$ 0.70
Exercise Price $0.82
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	12,135,922	12,135,922
Exercise price (in dollar per share) | $ / shares	$ 0.82
Exercise Price $0.67
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	2,230,080	2,230,080
Exercise price (in dollar per share) | $ / shares	$ 0.67
Exercise Price $1.00
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	2,999,975	2,999,975
Exercise price (in dollar per share) | $ / shares	$ 1
Exercise Price CAD 0.80
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	625,000	625,000
Exercise price (in dollar per share) | $ / shares		$ 0.80
Exercise Price CAD 0.80
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	500,000	500,000
Exercise price (in dollar per share) | $ / shares		$ 0.80

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) plan	Sep. 30, 2021 USD ($)	Sep. 30, 2022 $ / shares shares	Dec. 31, 2021 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans | plan			2
Exercisable options (in shares) | shares					47,549,343
Outstanding options (in shares) | shares					57,051,012	54,282,752
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike price (in dollar per share) | $ / shares					$ 0.10
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike price (in dollar per share) | $ / shares					$ 1.63
Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense | $	$ 0.9	$ 2.6	$ 2.3	$ 8
Equity Incentive Plan | Class A Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of stock options available for grant, percentage of number of outstanding shares			10%
Minimum exercise price of stock options issued, percentage of fair market value of shares on grant date			100%
Maximum term of stock options granted			10 years

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Number of Options
Number of options, beginning balance (in shares)	54,282,752
Number of options, granted (in shares)	7,460,000
Number of options, exercised (in shares)	(51,975)
Number of options, forfeited/ expired (in shares)	(4,639,765)
Number of options, ending balance (in shares)	57,051,012	54,282,752
Weighted Average Price CAD$
Weighted Average Price, Beginning Balance (in dollar per shares)	$ 0.94
Weighted Average Price, Granted (in dollar per shares)	0.82
Weighted Average Price, Exercised (in dollar per shares)	0.80
Weighted Average Price, Forfeited/ Expired (in dollar per shares)	1.01
Weighted Average Price, Ending Balance (in dollar per shares)	$ 0.89	$ 0.94
Weighted Average Years
Weighted average years	2 years 4 months 9 days	2 years 11 months 19 days
Weighted average years, granted	3 years 4 months 17 days

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options Values using Black-Scholes Model with Key Assumptions (Details) - Share-Based Payment Arrangement, Option	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-Free Interest Rate	3.62%
Risk-Free Interest Rate, minimum		0.87%
Risk-Free Interest Rate, maximum		0.92%
Expected Life	3 years 6 months	5 years
Expected Annualized Volatility	89.83%
Expected Annualized Volatility, maximum		93.53%
Expected Annualized Volatility, minimum		86.20%
Forfeiture rate	0%	0%
Expected Dividend Yield	0%	0%

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	May 10, 2019
Entity Related To iWolf Management, LLC | Management fees, pass through marketing costs and customer service
Leadership consulting Agreement In Force And Effect For A Period
Related party transaction, amounts of transaction	$ 0.3		$ 0.3
LI Lending, LLC | Chief Executive Officer
Leadership consulting Agreement In Force And Effect For A Period
Percentage of ownership interest held		14.28%
LI Lending, LLC | Director
Leadership consulting Agreement In Force And Effect For A Period
Percentage of ownership interest held		14.28%
LI Lending, LLC
Leadership consulting Agreement In Force And Effect For A Period
Maximum borrowing capacity under credit facility					$ 50
Long-term line of credit				$ 48.3
Line of credit facility, exit fee		$ 9
Amount due at maturity		54
Long-term debt, gross		49.7
Debt instrument, unamortized discount		0.3
Interest payable		$ 5.8
LI Lending LLC Note, as Amended
Leadership consulting Agreement In Force And Effect For A Period
Maximum borrowing capacity under credit facility					$ 45

Contingencies - Additional Info

Contingencies - Additional Information (Details)		9 Months Ended
	Jan. 26, 2022 USD ($) installment	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Outstanding balance of contingent consideration		$ 0	$ 2,400,000
Loss contingency damages sought value	$ 19,400,000
Loss contingency benefit value	129,000,000
Litigation settlement, amount	$ 250,000
Litigation settlement, number of installments | installment	5
Minimum
Loss Contingencies [Line Items]
Contingent consideration evaluation period		2 years
Maximum
Loss Contingencies [Line Items]
Contingent consideration evaluation period		3 years

Contingencies - Summary of Fair

Contingencies - Summary of Fair Value of Contingent Consideration (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Loss Contingency Accrual [Roll Forward]
Balance, December 31, 2021	$ 2,400,000
Balance, September 30, 2022	0
Less: current portion	9,299,000	$ 3,413,000
Long-term portion	0	$ 2,393,000
Om of Medicine
Loss Contingency Accrual [Roll Forward]
Balance, December 31, 2021	2,393,000
Changes in fair value	(2,393,000)
Balance, September 30, 2022	0
Less: current portion	0
Long-term portion	$ 0

Financial instruments and fin_3

Financial instruments and financial risk management - Schedule of Fair Value Measurements With in the Fair Value Hierarchy of The Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Liabilities:
Derivative liability	$ 8	$ 3,502
Total liabilities	8	3,502
Level 1
Liabilities:
Derivative liability	0	0
Total liabilities	0	0
Level 2
Liabilities:
Derivative liability	0	0
Total liabilities	0	0
Level 3
Liabilities:
Derivative liability	8	3,502
Total liabilities	$ 8	$ 3,502

Financial Instruments and Fin_4

Financial Instruments and Financial Risk Management - Summary of Changes in Fair Value of the Derivative Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 3,502	$ 5,807
(Gain) loss on fair value of derivative liability	(3,494)	(502)
Change in fair value of derivative liability upon exercise of warrants	0	(1,427)
Balance, end of period	$ 8	$ 3,878

Financial Instruments and Fin_5

Financial Instruments and Financial Risk Management - Additional information (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Investments, All Other Investments [Abstract]
Federally insured limits exceeded amount		$ 11
Maximum credit exposure	$ 18.4	$ 12.7

Financial instruments and fin_6

Financial instruments and financial risk management - Schedule of Gross Contractual Obligations (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Financial Instruments [Line Items]
Less than 1 year	$ 32,222
1 to 3 years	92,414
3 to 5 years	0
Greater than 5 years	0
Total	124,636
Accounts payable and accrued liabilities
Financial Instruments [Line Items]
Less than 1 year	22,923
1 to 3 years	1,200
3 to 5 years	0
Greater than 5 years	0
Total	24,123
Convertible notes, notes payable and accrued interest
Financial Instruments [Line Items]
Less than 1 year	9,299
1 to 3 years	75,214
3 to 5 years	0
Greater than 5 years	0
Total	84,513
Construction finance liability
Financial Instruments [Line Items]
Less than 1 year	0
1 to 3 years	16,000
3 to 5 years	0
Greater than 5 years	0
Total	$ 16,000

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information - Summary o

Segment Information - Summary of Revenues By Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenues	$ 32,474	$ 25,941	$ 86,961	$ 76,032
Total Net Loss	8,606	4,599	21,056	21,911
Total Assets	319,999		319,999		$ 255,539
Corporate
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Total Net Loss	9,020	3,269	17,487	15,920
Total Assets	443		443		15,801
THC Cannabis | Operating Segments
Segment Reporting Information [Line Items]
Revenues	32,308	25,529	86,286	74,073
Total Net Loss	(363)	949	3,739	4,790
Total Assets	318,717		318,717		238,933
CBD Wellness | Operating Segments
Segment Reporting Information [Line Items]
Revenues	166	412	675	1,959
Total Net Loss	(51)	$ 381	(170)	$ 1,201
Total Assets	$ 839		$ 839		$ 805

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense and Effective Tax Rates (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Net loss before income taxes	$ (5,279)	$ (53)	$ (11,239)	$ (11,351)
Income tax expense	$ (3,322)	$ (4,541)	$ (9,802)	$ (10,545)

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Thousands	Nov. 10, 2022 USD ($)	Oct. 27, 2022 USD ($)	Oct. 13, 2022 USD ($) defendant
Subsequent Event [Line Items]
Prepaid forward purchase agreement, amount			$ 3,750
Planned litigation, number of defendants | defendant			4
Prepaid forward purchase agreement, funder's share multiplier			1.5
Percent of the proceeds of the litigation after deducting multiple return			35%
Stated interest rate, if not repaid before October 2024			15%
IL Grown Medicine, LLC
Subsequent Event [Line Items]
Tenant improvement allowance, increase	$ 19,900
Remaining lease term	20 years
Increase in base rent	$ 200
Increase in security deposit	$ 2,200
Minimum | IL Grown Medicine, LLC
Subsequent Event [Line Items]
Tenant improvement allowance, increase option		$ 15,000
Maximum | IL Grown Medicine, LLC
Subsequent Event [Line Items]
Tenant improvement allowance, increase option		$ 19,900